Tinidazole is a nitroimidazole antimicrobial indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis, among other approved uses. It is available as tablets for oral use. MedsAcross supplies Tinidazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection.
Source: US FDA prescribing information
Tinidazole is an antiprotozoal, antibacterial agent.
Source: US FDA prescribing information
2 DOSAGE AND ADMINISTRATION Trichomoniasis: a single 2 g oral dose taken with food. Treat sexual partners with the same dose and at the same time. Giardiasis: Adults: a single 2 g dose taken with food. Pediatric patients older than three years of age: a single dose of 50 mg/kg (up to 2 g) with food. Amebiasis, Intestinal: Adults: 2 g per day for 3 days with food. Pediatric patients older than three years of age: 50 mg/kg/day (up to 2 g per day) for 3 days with food. Amebic liver abscess: Adults: 2 g per day for 3-5 days with food. Pediatric patients older than three years of age: 50 mg/kg/day (up to 2 g per day) for 3-5 days with food. Bacterial vaginosis: Adult women: 2 g once daily for 2 days taken with food, or 1 g once daily for 5 days taken with food
Source: US FDA prescribing information
The use of tinidazole is contraindicated: In patients with a previous history of hypersensitivity to tinidazole or other nitroimidazole derivatives. Reported reactions have ranged in severity from urticaria to Stevens-Johnson syndrome. In patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole, another nitroimidazole drug, structurally related to tinidazole, in patients with Cockayne syndrome Prior history of hypersensitivity to tinidazole or other nitroimidazole derivatives. Patients with Cockayne syndrome
Source: US FDA prescribing information
Boxed warning (potential risk for carcinogenicity warning: potential risk for carcinogenicity): Carcinogenicity has been seen in mice and rats treated chronically with metronidazole, another nitroimidazole agent. Although such data have not been reported for tinidazole, the two drugs are structurally related and have similar biologic effects. Limit use of TINIDAZOLE to approved indications only. Avoid chronic use. Avoid chronic use. Seizures and neuropathy have been reported. Discontinue tinidazole if abnormal neurologic signs develop. Vaginal candidiasis may develop with tinidazole and require treatment with an antifungal agent. Use tinidazole with caution in patients with blood dyscrasias. Tinidazole may produce transient leukopenia and neutropenia
Source: US FDA prescribing information
Most common adverse reactions for a single 2 g dose of tinidazole (incidence >1%) are metallic/bitter taste, nausea, weakness/fatigue/malaise, dyspepsia/cramps/epigastric discomfort, vomiting, anorexia, headache, dizziness and constipation
Source: US FDA prescribing information
Although not specifically identified in studies with tinidazole, the following drug interactions were reported for metronidazole, a chemically-related nitroimidazole. Therefore, these drug interactions may occur with tinidazole. The following drug interactions were reported for metronidazole, a chemically-related nitroimidazole and may therefore occur with tinidazole: Warfarin and other oral coumarin anticoagulants: Anticoagulant dosage may need adjustment during and up to 8 days after tinidazole therapy. Alcohol-containing beverages/preparations: Avoid during and up to 3 days after tinidazole therapy. Lithium: Monitor serum lithium concentrations. Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs. Fluorouracil: Monitor for fluorouracil-associated toxicities. Phenytoin, fosphenytoin: Adjustment of anticonvulsant and/or tinidazole dose(s) may be needed.
Source: US FDA prescribing information
Store at controlled room temperature 20-25° C (68-77° F), excursions permitted to 15-30° C (59-86° F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
6 presentations of Tinidazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tinidazole 500 mg tabletOralGeneric name | — | US FDA | Available on request |
| Tinidazole 250 mg tabletOralGeneric name | — | US FDA | Available on request |
| Tindazole 500 mg tabletOral | Rising Pharma Holdings | US FDA | Available on request |
| Tindamax 500 mg tabletOral | Mission Pharmacal | US FDA | Available on request |
| Tindamax 250 mg tabletOral | Mission Pharmacal | US FDA | Available on request |
| Tindazole 250 mg tabletOral | Rising Pharma Holdings | US FDA | Available on request |
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 17 May 2004 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Tinidazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 6 presentations of Tinidazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Tinidazole, including Tindamax, Tindazole.
Yes. The US FDA first approved Tinidazole on 17 May 2004, according to Drugs@FDA.
No listed presentation of Tinidazole is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tinidazole is classified under ATC code J01XD02 (Tinidazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.